This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Celgene, Bristol-Myers move to dismiss US antitrust claims over Thalomid, Revlimid

( November 15, 2022, 16:02 GMT | Official Statement) -- MLex Summary: Celgene and Bristol-Myers Squibb moved to dismiss claims that they illegally monopolized the market for Thalomid and Revlimid, saying that plaintiffs fail to show any sham litigation. “If plaintiffs’ allegations suffice to plead sham litigation in that circumstance, any patent case that does not yield a final judgment for the patentee on every claim of every patent may be called a ‘sham.’ That is not the law,” the companies argued. See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections